AbbVie Collaborates with Caraway to Develop TMEM175 for Parkinson’s Disease and Other Related Disorders

 AbbVie Collaborates with Caraway to Develop TMEM175 for Parkinson’s Disease and Other Related Disorders

AbbVie Collaborates with Caraway to Develop TMEM17 for Parkinson’s Disease and Other Related Disorders

Shots:

  • Caraway to receive ~$267M including $17M up front in cash and remaining as option payment & milestones and is eligible for additional regulatory and commercial milestones along with royalties & gets the option to take part in product development in exchange for higher royalty rates
  • Post pre-clinical research and development activities, AbbVie has an option to license the program and proceed with IND-enabling studies, clinical development, and commercialization
  • The collaboration leverages Caraway’s drug discovery platform, expertise in lysosomal biology & cellular clearance mechanisms combine with AbbVie’s expertise in disease biology, clinical development, and global commercialization

Click here to­ read full press release/ article | Ref: Business Wire | Image: Business Wire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post